SLFN14

Summary

SLFN14 (schlafen family member 14, HGNC:32689) is a protein-coding gene on chromosome 17q12, encoding Protein SLFN14 (P0C7P3). Shows no ribosome-associated and endoribonuclease activities.

The protein encoded by this gene plays an important role in platelet formation and function. Defects in this gene are a cause of thrombocytopenia with excessive bleeding.

Source: NCBI Gene 342618 — RefSeq curated summary.

At a glance

• Gene–disease (curated): platelet-type bleeding disorder 20 (Strong, GenCC)
• GWAS associations: 27
• Clinical variants (ClinVar): 168 total — 2 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 5
• MANE Select transcript: NM_001129820

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32689
Approved symbol	SLFN14
Name	schlafen family member 14
Location	17q12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000236320
Ensembl biotype	protein_coding
OMIM	614958
Entrez	342618

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000415846, ENST00000674182

RefSeq mRNA: 1 — MANE Select: NM_001129820 NM_001129820

CCDS: CCDS45650

Canonical transcript exons

ENST00000674182 — 6 exons

Exon	Start	End
ENSE00001617251	35552730	35553444
ENSE00001730685	35554576	35554704
ENSE00003898058	35559727	35559805
ENSE00003898150	35560767	35560819
ENSE00003898458	35557003	35558106
ENSE00003898902	35543985	35549073

Expression profiles

Bgee: expression breadth broad, 35 present calls, max score 74.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6850 / max 335.3675, expressed in 61 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165382	0.6569	60
165383	0.0281	13

Top tissues by expression

99 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	74.00	gold quality
leukocyte	CL:0000738	73.39	gold quality
bone marrow cell	CL:0002092	72.70	gold quality
bone marrow	UBERON:0002371	71.87	gold quality
blood	UBERON:0000178	63.35	gold quality
granulocyte	CL:0000094	59.67	gold quality
colonic epithelium	UBERON:0000397	58.80	gold quality
lymph node	UBERON:0000029	54.83	gold quality
spleen	UBERON:0002106	54.69	gold quality
right lung	UBERON:0002167	51.08	gold quality
right uterine tube	UBERON:0001302	49.99	gold quality
vermiform appendix	UBERON:0001154	49.72	gold quality
placenta	UBERON:0001987	49.43	gold quality
lung	UBERON:0002048	47.85	gold quality
upper lobe of left lung	UBERON:0008952	47.10	gold quality
small intestine Peyer’s patch	UBERON:0003454	46.95	gold quality
small intestine	UBERON:0002108	46.59	gold quality
tonsil	UBERON:0002372	44.83	silver quality
gall bladder	UBERON:0002110	44.53	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	44.37	silver quality
ganglionic eminence	UBERON:0004023	43.89	gold quality
ventricular zone	UBERON:0003053	43.29	gold quality
cortical plate	UBERON:0005343	43.11	gold quality
adrenal tissue	UBERON:0018303	43.11	silver quality
liver	UBERON:0002107	42.83	silver quality
hindlimb stylopod muscle	UBERON:0004252	41.64	gold quality
duodenum	UBERON:0002114	41.41	gold quality
rectum	UBERON:0001052	41.36	gold quality
right lobe of liver	UBERON:0001114	40.85	silver quality
primary visual cortex	UBERON:0002436	40.78	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

7 targeting SLFN14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-8078	98.32	65.73	361
HSA-MIR-4421	97.99	64.89	701
HSA-MIR-5699-3P	97.81	65.00	861
HSA-MIR-6500-3P	97.42	67.20	867

Literature-anchored findings (GeneRIF, showing 9)

• These results identify SLFN14 mutations as cause for an inherited thrombocytopenia with excessive bleeding, outlining a fundamental role for SLFN14 in platelet formation and function. (PMID:26280575)
• In a family with three affected individuals we found the c.667C>T variant in SLFN14 predicted to result in the p.Arg223Trp substitution within the ATPase- AAA-4 domain of SLFN14. The variant segregated with macrothrombocytopenia within the pedigree. (PMID:26769223)
• these data suggest that SLFN14 is a novel antiviral factor for both DNA and RNA viruses (PMID:28734654)
• SLFN14 colocalizes with ribosomes and causes the endoribonucleolytic degradation of rRNA in cells. (PMID:29678925)
• The mutations of c.1187delT of PCDHGA4 and c.2557insC of SLFN14 may be pathogenic factors contributing to the development of ASD. (PMID:30536060)
• SLFN14 gene mutations associated with bleeding. (PMID:31378119)
• [SLFN14 inhibits LINE-1 transposition activity]. (PMID:32694106)
• Ribosome dysfunction underlies SLFN14-related thrombocytopenia. (PMID:36790527)
• Schlafen14 Impairs HIV-1 Expression in a Codon Usage-Dependent Manner. (PMID:38675845)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slfn14	ENSMUSG00000082101
rattus_norvegicus	AC118772.1	ENSRNOG00000009709

Paralogs (6): SLFN13 (ENSG00000154760), SLFN5 (ENSG00000166750), SLFNL1 (ENSG00000171790), SLFN12 (ENSG00000172123), SLFN11 (ENSG00000172716), SLFN12L (ENSG00000205045)

Protein

Protein identifiers

Protein SLFN14 — P0C7P3 (reviewed: P0C7P3)

All UniProt accessions (1): P0C7P3

UniProt curated annotations — full annotation on UniProt →

Function. Shows no ribosome-associated and endoribonuclease activities. Displays polysome-associated endoribonuclease activity towards mRNAs and rRNAs. May play a role in RNA surveillance pathways by recognizing stalled ribosomes and triggering endonucleolytic cleavage of aberrant mRNAs. Cleaves different types of rRNAs and mRNAs in a magnesium- and manganese-dependent and ATP-independent manner. Involved in correct maturation of megakaryocytes and especially important for proplatelet extension.

Subunit / interactions. Associates with ribosomes in an ATP-independent manner.

Subcellular location. Nucleus.

Tissue specificity. Expressed in megakaryocytes and platelets (at protein level). Weakly expressed in melanocytes and malignant melanoma cells.

Disease relevance. Bleeding disorder, platelet-type, 20 (BDPLT20) [MIM:616913] A disorder characterized by increased bleeding tendency due to platelet dysfunction. Clinical features include epistaxis, hematomas, bleeding after tooth extraction, and menorrhagia. BDPLT20 is characterized by moderate thrombocytopenia and platelet secretion defects. Inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Cofactor. C-terminally truncated SLFN14 endoribonuclease requires manganese and magnesium for its endoribonuclease activity.

Similarity. Belongs to the Schlafen family. Subgroup III subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P0C7P3-1	1	yes
P0C7P3-2	2

RefSeq proteins (1): NP_001123292* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007421	Schlafen_AlbA_2_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR029684	Schlafen	Family
IPR031450	Poxin-SLFN/SLFN_N	Domain
IPR038461	Schlafen_AlbA_2_dom_sf	Homologous_superfamily
IPR048729	SLFN_GTPase-like	Domain

Pfam: PF04326, PF17057, PF21026

UniProt features (19 total): sequence variant 10, chain 2, mutagenesis site 2, region of interest 2, sequence conflict 1, binding site 1, splice variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9NYY	ELECTRON MICROSCOPY	2.73
9JR9	ELECTRON MICROSCOPY	2.84
9UIE	ELECTRON MICROSCOPY	2.88
9JN9	ELECTRON MICROSCOPY	3.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0C7P3-F1	83.82	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 593–600

Mutagenesis-validated functional residues (2):

Position	Phenotype
248	reduces endoribonuclease activity.
249	abolishes endoribonuclease activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 55 (showing top): GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_RESPONSE_TO_METAL_ION, GOBP_RESPONSE_TO_MAGNESIUM_ION, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOMF_RNA_ENDONUCLEASE_ACTIVITY, GOBP_CELL_MATURATION, GOBP_RRNA_CATABOLIC_PROCESS, GOBP_RESPONSE_TO_MANGANESE_ION, GOMF_RIBONUCLEOPROTEIN_COMPLEX_BINDING, GOMF_RIBOSOME_BINDING, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOBP_CELLULAR_RESPONSE_TO_MAGNESIUM_ION

GO Biological Process (5): mRNA catabolic process (GO:0006402), rRNA catabolic process (GO:0016075), platelet maturation (GO:0036345), cellular response to magnesium ion (GO:0071286), cellular response to manganese ion (GO:0071287)

GO Molecular Function (8): RNA endonuclease activity (GO:0004521), ATP binding (GO:0005524), hydrolase activity (GO:0016787), ribosome binding (GO:0043022), nucleotide binding (GO:0000166), nuclease activity (GO:0004518), endonuclease activity (GO:0004519), RNA nuclease activity (GO:0004540)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA catabolic process	2
cellular response to metal ion	2
nuclease activity	2
negative regulation of gene expression	1
mRNA metabolic process	1
rRNA metabolic process	1
cell maturation	1
response to magnesium ion	1
response to manganese ion	1
endonuclease activity	1
RNA nuclease activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
catalytic activity	1
ribonucleoprotein complex binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
catalytic activity, acting on a nucleic acid	1
catalytic activity, acting on RNA	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

272 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLFN14	NBEAL2	Q6ZNJ1	380
SLFN14	PRSS33	Q8NF86	379
SLFN14	ANKRD26	Q9UPS8	379
SLFN14	ITPRID1	Q6ZRS4	368
SLFN14	PTRHD1	Q6GMV3	363
SLFN14	FYB1	O15117	360
SLFN14	PTRH1	Q86Y79	359
SLFN14	ZNF575	Q86XF7	348
SLFN14	GNE	Q9Y223	348
SLFN14	ZNF701	Q9NV72	348
SLFN14	GFI1B	Q5VTD9	324
SLFN14	ZNF425	Q6IV72	324
SLFN14	MPIG6B	O95866	323
SLFN14	ACTN1	P12814	322
SLFN14	PDE3A	Q14432	314

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SLFN14	S100A10	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (5): S100A10 (Proximity Label-MS), EEF2 (Cross-Linking-MS (XL-MS)), SLFN14 (Cross-Linking-MS (XL-MS)), SLFN14 (Cross-Linking-MS (XL-MS)), TAF1C (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A140LIF8, A0JN92, A1Z198, A6H603, B1ARD6, B1ARD8, D9I2F9, D9I2G1, D9I2G3, D9I2G4, D9I2H0, E1BPN0, G1SRW8, O02799, P0C7P3, P52630, Q08AF3, Q0GKD5, Q0P3U3, Q149M9, Q1LXZ7, Q1LZ50, Q2LKU9, Q2LKV5, Q2LKW6, Q32KW9, Q5I0J8, Q5NCI0, Q5RCZ8, Q5RFJ8, Q5SY16, Q5U311, Q60766, Q63035, Q68D06, Q6AYC2, Q6AYF9, Q6IEE8, Q6NXR0, Q7Z7L1

Diamond homologs: A0A7H0DNF0, B1ARD6, B1ARD8, G1SRW8, P0C7P3, Q08AF3, Q5RCZ8, Q5U311, Q68D06, Q6IEE8, Q7Z7L1, Q8CBA2, Q8IYM2, Q8V4S4, Q9Z0I6, Q9Z0I7, V9GXG1, Q8QMP8, Q01226, P21000

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

168 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	121
Likely benign	18
Benign	9

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
225536	NM_001129820.2(SLFN14):c.667C>T (p.Arg223Trp)	Pathogenic
988815	NM_001129820.2(SLFN14):c.3_4insCTAGTCGACTATA (p.Glu2fs)	Pathogenic
225535	NM_001129820.2(SLFN14):c.652A>G (p.Lys218Glu)	Likely pathogenic

SpliceAI

676 predictions. Top by Δscore:

Variant	Effect	Δscore
17:35549069:GTTGG:G	acceptor_gain	0.9900
17:35549071:TGG:T	acceptor_gain	0.9900
17:35549074:C:CC	acceptor_gain	0.9900
17:35551668:AACTC:A	donor_gain	0.9900
17:35551669:A:C	donor_gain	0.9900
17:35552728:A:AC	donor_gain	0.9900
17:35552729:C:CC	donor_gain	0.9900
17:35556995:C:A	donor_gain	0.9900
17:35557041:G:C	donor_gain	0.9900
17:35549070:TTGG:T	acceptor_gain	0.9800
17:35549071:TGGCT:T	acceptor_loss	0.9800
17:35549072:GG:G	acceptor_gain	0.9800
17:35549072:GGCTG:G	acceptor_loss	0.9800
17:35549073:GCT:G	acceptor_loss	0.9800
17:35549074:C:A	acceptor_loss	0.9800
17:35549075:T:G	acceptor_loss	0.9800
17:35556994:T:TA	donor_gain	0.9800
17:35557002:CCTGA:C	donor_gain	0.9800
17:35551668:AACT:A	donor_gain	0.9700
17:35552729:CGTCA:C	donor_gain	0.9700
17:35556997:CTTTA:C	donor_loss	0.9700
17:35556998:TTTAC:T	donor_loss	0.9700
17:35556999:TTACC:T	donor_loss	0.9700
17:35557000:TA:T	donor_loss	0.9700
17:35557001:ACCTG:A	donor_loss	0.9700
17:35557002:C:CT	donor_loss	0.9700
17:35557027:C:CT	donor_gain	0.9700
17:35549076:G:C	acceptor_gain	0.9600
17:35553445:C:CC	acceptor_gain	0.9600
17:35557033:A:AC	donor_gain	0.9600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000117842 (17:35548753 A>G), RS1000176525 (17:35547333 G>A), RS1000953465 (17:35560366 C>A), RS1000974454 (17:35546956 A>G), RS1001003261 (17:35549499 TGCAAAAAAAGCA>T), RS1001133275 (17:35553340 A>T), RS1001314751 (17:35558495 C>T), RS1001436264 (17:35552379 G>A), RS1001441 (17:35549064 G>A,T), RS1001636290 (17:35551018 T>G), RS1001683986 (17:35558752 A>C,G), RS1001841871 (17:35555599 G>A), RS1002189455 (17:35544579 A>AGT), RS1002241160 (17:35545425 T>C), RS1002366717 (17:35562694 C>T)

Disease associations

OMIM: gene MIM:614958 | disease phenotypes: MIM:616913

GenCC curated gene-disease

Disease	Classification	Inheritance
platelet-type bleeding disorder 20	Strong	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
platelet-type bleeding disorder 20	Moderate	AD

Mondo (2): platelet-type bleeding disorder 20 (MONDO:0014830), thrombocytopenia (MONDO:0002049)

Orphanet (1): Autosomal dominant thrombocytopenia with platelet secretion defect (Orphanet:466806)

HPO phenotypes

5 total (5 of 5 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000132	Menorrhagia
HP:0000421	Epistaxis
HP:0000978	Bruising susceptibility
HP:0001873	Thrombocytopenia

GWAS associations

27 associations (top):

Study	Trait	p-value
GCST002431_6	Response to radiotherapy in cancer (late toxicity)	8.000000e-06
GCST004599_121	Mean platelet volume	5.000000e-10
GCST004603_177	Platelet count	9.000000e-14
GCST004603_178	Platelet count	4.000000e-16
GCST004607_73	Plateletcrit	3.000000e-17
GCST004616_26	Platelet distribution width	6.000000e-48
GCST004616_27	Platelet distribution width	8.000000e-33
GCST004616_28	Platelet distribution width	7.000000e-40
GCST004628_18	Immature fraction of reticulocytes	1.000000e-10
GCST005991_42	Platelet count	1.000000e-12
GCST90002387_27	Immature fraction of reticulocytes	2.000000e-13
GCST90002395_251	Mean platelet volume	2.000000e-23
GCST90002395_253	Mean platelet volume	2.000000e-109
GCST90002400_209	Plateletcrit	5.000000e-47
GCST90002400_210	Plateletcrit	1.000000e-09
GCST90002401_588	Platelet distribution width	9.000000e-127
GCST90002401_589	Platelet distribution width	5.000000e-30
GCST90002401_590	Platelet distribution width	8.000000e-28
GCST90002401_591	Platelet distribution width	5.000000e-14
GCST90002401_592	Platelet distribution width	3.000000e-31
GCST90002401_593	Platelet distribution width	5.000000e-265
GCST90002402_448	Platelet count	5.000000e-17
GCST90002402_449	Platelet count	2.000000e-110
GCST90002402_450	Platelet count	9.000000e-33
GCST90002404_159	Red cell distribution width	5.000000e-21
GCST90002405_324	Reticulocyte count	1.000000e-13
GCST90002406_456	Reticulocyte fraction of red cells	3.000000e-21

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0007984	platelet component distribution width
EFO:0007986	reticulocyte count
EFO:0009188	Red cell distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

3 total (human), top 3 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

240 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia
NCT03326843	PHASE3	TERMINATED	Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03515096	PHASE3	COMPLETED	Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT05563064	PHASE3	UNKNOWN	Effect of Herbal Formulation on Thrombocytes Count
NCT07442513	PHASE3	RECRUITING	Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT